Chronic obstructive pulmonary disease (COPD) affects more than 400 million people, continues to be the third cause of death ...

“Air quality has a direct impact on those with asthma and COPD, and we’re proud to collaborate with the American Lung Association to provide our patients with the education and resources they need to ...

Digital inhalers can detect significant changes in physiologic and inhaler use metrics in the 14 days before COPD exacerbations.

For $10 billion, Merck is acquiring a promising healthcare company which is in the early stages of its growth. Key to its ...

This educational activity is intended for pulmonary specialists and other members of the health care team who care for patients with obstructive lung diseases such as COPD and asthma. Asthma and ...

According to the World Health Organization (WHO), chronic obstructive pulmonary disease (COPD) is the third leading cause of ...

Dupilumab reduces COPD exacerbations and Type 2 inflammation biomarkers, with strongest benefit in patients with high ...

This acquisition of Verona Pharma reflects the commitment we have to delivering innovative treatments to patients and our ...

After the Veterans Health Administration tweaked its formulary on an asthma and chronic obstructive pulmonary disease therapy, hospitalizations and emergency department visits increased, according to ...

Verona Pharma, a year after receiving regulatory approval for its landmark chronic obstructive pulmonary disease (COPD) treatment, is being acquired by pharmaceutical giant Merck in a deal worth about ...

Verona Pharma brings to Merck the inhaled drug Ohtuvayre, which is FDA approved as a treatment for chronic obstructive ...

The move bolsters Merck's lineup as it braces for the 2028 loss of patent exclusivity for blockbuster cancer drug Keytruda.